Piper Sandler Has Lowered Expectations for Tvardi Therapeutics (NASDAQ:TVRD) Stock Price

Tvardi Therapeutics (NASDAQ:TVRD) had its price target lowered by Piper Sandler from $4.00 to $3.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Piper Sandler’s price objective indicates a potential upside of 1.18% from the company’s previous close.

Several other research firms have also recently issued reports on TVRD. Wall Street Zen raised shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Finally, Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.00.

Tvardi Therapeutics Price Performance

Shares of NASDAQ:TVRD traded down $0.22 on Wednesday, hitting $2.97. 81,013 shares of the company’s stock were exchanged, compared to its average volume of 62,813. Tvardi Therapeutics has a 12 month low of $2.81 and a 12 month high of $43.65. The stock has a market capitalization of $27.81 million, a price-to-earnings ratio of -0.31 and a beta of 0.14. The business’s 50 day simple moving average is $3.81 and its two-hundred day simple moving average is $9.00.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new position in Tvardi Therapeutics during the 4th quarter valued at about $55,000. Quadrature Capital Ltd purchased a new stake in shares of Tvardi Therapeutics in the 4th quarter worth approximately $90,000. Russell Investments Group Ltd. boosted its stake in shares of Tvardi Therapeutics by 1,351.5% during the fourth quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock valued at $69,000 after purchasing an additional 14,866 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Tvardi Therapeutics by 534.3% during the fourth quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock valued at $223,000 after purchasing an additional 43,619 shares in the last quarter. Finally, Arax Advisory Partners increased its holdings in Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after buying an additional 6,173 shares during the period. 44.66% of the stock is currently owned by institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.